A Simply Modified Lymphocyte for Systematic Cancer Therapy

Area of Science:

• Oncology
• Immunotherapy
• Biomedical Engineering

Background:

• Cytotherapy is a growing field in cancer treatment, with ongoing research into modifying cells for enhanced efficacy.
• Existing methods for cell modification often involve complex chemical or genetic approaches.

Purpose of the Study:

• To develop a simple, clinically applicable method for modifying lymphocytes for cancer therapy.
• To investigate the use of δ-aminolevulinic acid (δ-ALA) for targeted cancer treatment.
• To evaluate a novel strategy for enhanced delivery of anti-cancer agents via modified lymphocytes.

Main Methods:

• Lymphocytes were incubated with δ-aminolevulinic acid (δ-ALA) to induce synthesis of protoporphyrin X (PpIX).
• Tumor-targeted lymphocytes loaded with PpIX were subjected to 630 nm laser irradiation, generating apoptotic bodies (Ab).
• A microfluidic device was developed for simplified cell sorting and drug synthesis in a one-step process.

Main Results:

• δ-ALA-treated lymphocytes specifically accumulated in cancer tissues and synthesized anti-neoplastic PpIX.
• Laser irradiation of lymphocytes generated PpIX-containing apoptotic bodies, leading to effective killing of Ras-mutated cancer cells.
• In vitro and in vivo studies demonstrated the efficacy of this easy-operated and globally-regulated cancer therapy strategy.

Conclusions:

• This novel cytotherapy strategy offers a simple and effective method for cancer treatment.
• The use of δ-ALA and laser-activated lymphocytes shows significant therapeutic potential, particularly for Ras-mutated cancers.
• The developed microfluidic device facilitates the translation and generalization of this innovative cancer therapy approach.